A Multi-Center, Open-Label, Phase 1 Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
Latest Information Update: 09 Feb 2026
At a glance
- Drugs Antineoplastics (Primary) ; Interleukin-12 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Innovent Biologics
Most Recent Events
- 04 Feb 2026 Status changed from not yet recruiting to recruiting.
- 16 Jan 2026 New trial record